A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Study Purpose

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Age>=18Y.
  • - Good Organ Function.
  • - Expected survival time ≥ 3 months.
  • - advanced melanoma with BRAF V600 mutation that have been diagnosed.
  • - ECOG score 0-1;

    Exclusion Criteria:

    - Previous treatment with BRAF inhibitors or MEK inhibitors.
  • - Symptomatic brain or meningeal metastases (unless the patient has beenon > treatment for 3 months, has no evidence of progress on imagingwithin 4 weeks prior to initial administration, and tumor-related clinicalsymptoms are stable).
  • - Severe active infections requiring systemic anti-infective therapy.
  • - A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05114603
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Shanghai Henlius Biotech
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Advanced Melanoma
Arms & Interventions

Arms

Experimental: Dose-escalation stage

Iinvestigate the safety and determine the MTD of HLX208. Two dose levels of 600mg and 900 mg are planned for dose finding.

Experimental: Dose-expansion stage

Patients with advanced melanoma will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX208.

Interventions

Drug: - HLX208

level 1:600mg po Bid level 2:900mg po Bid

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Peking University Cancer Hospita, Peking, Beijing, China

Status

Recruiting

Address

Peking University Cancer Hospita

Peking, Beijing, 100142

Site Contact

Lu Si, MD PhD

[email protected]

88196391

Hunan cancer hospital, Changsha, China

Status

Recruiting

Address

Hunan cancer hospital

Changsha, ,

Site Contact

Xingxiang Pu

[email protected]

88196391

Chendu, China

Status

Not yet recruiting

Address

West China Hospital of Sichuan University

Chendu, ,

Site Contact

Jiyan Liu

[email protected]

88196391

Fujian cancer hospital, Fujian, China

Status

Not yet recruiting

Address

Fujian cancer hospital

Fujian, ,

Site Contact

Yu Chen

[email protected]

88196391

Shangxi Bethune Hospita, Taiyuan, China

Status

Not yet recruiting

Address

Shangxi Bethune Hospita

Taiyuan, ,

Site Contact

Huijing feng

[email protected]

88196391

Wuhan, China

Status

Not yet recruiting

Address

union Hospital Tongji Medical College, Huazhong University of Science and Technology

Wuhan, ,

Site Contact

Jing Chen

[email protected]

88196391

Henan cancer hospital, Zhengzhou, China

Status

Not yet recruiting

Address

Henan cancer hospital

Zhengzhou, ,

Site Contact

Weitao Yao

[email protected]

88196391

Stay Informed & Connected